{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:14:08Z","timestamp":1793834048532,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002636","name":"Inje University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.biopha.2021.112463","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T19:50:24Z","timestamp":1637869824000},"page":"112463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy"],"prefix":"10.1016","volume":"145","author":[{"given":"Amy Hyein","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Eun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112463_bib1","unstructured":"What is Heart Failure? [updated May 31, 2017. Available from: \u3008https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\u3009."},{"key":"10.1016\/j.biopha.2021.112463_bib2","author":"Porter","year":"2011","journal-title":"Merck Man. Diagn. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2021.112463_bib3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.biopha.2021.112463_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Emerging Risk Factors","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.biopha.2021.112463_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2337\/dc17-2583","article-title":"Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction","volume":"41","author":"R\u00f8rth","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/dci17-0052","article-title":"Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes","volume":"41","author":"Packer","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.biopha.2021.112463_bib8","first-page":"1056","article-title":"When and for whom should we use SGLT2 inhibitors in HFrEF?","volume":"8","author":"Tanaka","year":"2020","journal-title":"JACC: Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here?\u00a0Reflections from a diabetes care editors\u2019 expert forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.biopha.2021.112463_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2019.12.011","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"JACC Heart Fail."},{"issue":"3","key":"10.1016\/j.biopha.2021.112463_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36628\/ijhf.2020.0010","article-title":"Paradigm shifts of heart failure therapy: do we need another paradigm?","volume":"2","author":"Lee","year":"2020","journal-title":"Int. J. Heart Fail."},{"issue":"24","key":"10.1016\/j.biopha.2021.112463_bib12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans administration cooperative study","volume":"314","author":"Cohn","year":"1986","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.112463_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199108013250508","article-title":"ACE inhibitors--a cornerstone of the treatment of heart failure","volume":"325","author":"Braunwald","year":"1991","journal-title":"New Engl. J. Med."},{"issue":"23","key":"10.1016\/j.biopha.2021.112463_bib14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.112463_bib15","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2021.112463_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2019.04.067","article-title":"The evolution of beta-blockers in coronary artery disease and heart failure (Part 1\/5)","volume":"74","author":"Joseph","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112463_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2021.112463_bib18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112463_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.biopha.2021.112463_bib20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/CIRCULATIONAHA.120.048365","article-title":"Victims of success in failure","volume":"142","author":"Lam","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2021.112463_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112463_bib22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2147\/DDDT.S84782","article-title":"Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date","volume":"10","author":"Vilela-Martin","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112463_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","article-title":"The role of natriuretic peptides in cardioprotection","volume":"69","author":"Nishikimi","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2021.112463_bib24","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ihj.2018.01.002","article-title":"Sacubitril\/valsartan: a novel angiotensin receptor-neprilysin inhibitor","volume":"70","author":"Dargad","year":"2018","journal-title":"Indian Heart J."},{"issue":"2","key":"10.1016\/j.biopha.2021.112463_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.112463_bib26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium\u2013glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.biopha.2021.112463_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.biopha.2021.112463_bib28","unstructured":"U.S. FDA approves Jardiance\u00ae (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease [Available from: \u3008https:\/\/www.boehringer-ingelheim.us\/press-release\/us-fda-approves-jardiance-empagliflozin-tablets-reduce-risk-cardiovascular-death\u3009."},{"issue":"22","key":"10.1016\/j.biopha.2021.112463_bib29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib30","first-page":"147","article-title":"Vascular nitric oxide: formation and function","volume":"2010","author":"Jin","year":"2010","journal-title":"J. Blood Med"},{"issue":"2","key":"10.1016\/j.biopha.2021.112463_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the Victoria trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail."},{"issue":"2","key":"10.1016\/j.biopha.2021.112463_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2021.112463_bib33","unstructured":"B. Sadeh, J.C. Fang, A New Class of Inotropes: Omecamtiv Mecarbil2021. Available from: \u3008https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2021\/02\/01\/14\/46\/a-new-class-of-inotropes\u3009."},{"issue":"4","key":"10.1016\/j.biopha.2021.112463_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.biopha.2021.112463_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3389\/fphys.2020.00696","article-title":"Neuregulin, an effector on mitochondria metabolism that preserves insulin sensitivity","volume":"11","author":"Guma","year":"2020","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/eurjhf\/hfq152","article-title":"Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses","volume":"13","author":"Jabbour","year":"2011","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.biopha.2021.112463_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006288","article-title":"Mechanisms of the multitasking endothelial protein NRG-1 as a compensatory factor during chronic heart failure","volume":"12","author":"De Keulenaer","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib38","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2021.112463_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112463_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","article-title":"Interleukin-1beta induces a reversible cardiomyopathy in the mouse","volume":"62","author":"Van Tassell","year":"2013","journal-title":"Inflamm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"J. Cardiovasc. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2021.112463_bib42","doi-asserted-by":"crossref","first-page":"H1553","DOI":"10.1152\/ajpheart.00158.2018","article-title":"Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury","volume":"315","author":"Toldo","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"22","key":"10.1016\/j.biopha.2021.112463_bib43","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","article-title":"Interleukin-1 blockade in cardiovascular diseases: a clinical update","volume":"39","author":"Buckley","year":"2018","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.biopha.2021.112463_bib44","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kluck","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"50","key":"10.1016\/j.biopha.2021.112463_bib45","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/j.biopha.2021.112463_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0323-2","article-title":"Heart failure with preserved ejection fraction: present status and future directions","volume":"51","author":"Yoon","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.biopha.2021.112463_bib47","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00392-020-01633-w","article-title":"Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future","volume":"109","author":"Wintrich","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.biopha.2021.112463_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","author":"Anker","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"16","key":"10.1016\/j.biopha.2021.112463_bib49","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2021.112463_bib50","article-title":"Heart failure population with therapeutic response to sacubitril\/valsartan, spironolactone and candesartan: FDA perspective","author":"Gandotra","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2021.112463_bib51","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112463_bib52","unstructured":"Neale T. New FDA Indication Opens Up Use of Sacubitril\/Valsartan in HfpEF 2021. Available from: \u3008https:\/\/www.tctmd.com\/news\/new-fda-indication-opens-use-sacubitrilvalsartan-hfpef\u3009."},{"issue":"3","key":"10.1016\/j.biopha.2021.112463_bib53","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/cts.12859","article-title":"Early clinical experience with AZD4831, a novel myeloperoxidase inhibitor, developed for patients with heart failure with preserved ejection fraction","volume":"14","author":"Nelander","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112463_bib54","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/bcp.13855","article-title":"Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers","volume":"85","author":"Gan","year":"2019","journal-title":"Br. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112463_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1389557515666150909143737","article-title":"Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases","volume":"16","author":"Grewal","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.biopha.2021.112463_bib56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fphar.2012.00087","article-title":"Aldose reductase, oxidative stress, and diabetic mellitus","volume":"3","author":"Tang","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112463_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046549","article-title":"Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia","volume":"7","author":"Son","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2021.112463_bib58","article-title":"Abstract 13475: clinical assessment of AT-001, an aldose reductase inhibitor in development for diabetic cardiomyopathy: a 28-day proof of concept study","volume":"140","author":"Perfetti","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2021.112463_bib59","doi-asserted-by":"crossref","unstructured":"C. Zhu, Aldose reductase inhibitors as potential therapeutic drugs of diabetic complications: chapter; 2013 23 January 2013.","DOI":"10.5772\/54642"},{"key":"10.1016\/j.biopha.2021.112463_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.12.060","article-title":"Overcoming the safety challenges of aldose reductase inhibition: development of AT-001 for diabetic cardiomyopathy","volume":"104","author":"Perfetti","year":"2020","journal-title":"Metabolism"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222101249X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222101249X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:43:48Z","timestamp":1781765028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222101249X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":60,"alternative-id":["S075333222101249X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112463","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112463"}}